219949-89-0

Basic information

• Product Name: Methyl 8-fluoro-4-hydroxyquinoline-2-carboxylate
• Synonyms: Methyl 8-fluoro-4-hydroxyquinoline-2-carboxylate;8-Fluoro-4-hydroxy-quinoline-2-carboxylic acid Methyl ester
• CAS NO: 219949-89-0
• Molecular Formula: C₁₁H₈FNO₃
• Molecular Weight: 221.18
• Mol File: 219949-89-0.mol

Chemical Properties

• Appearance: /
• Density: 1.406
• CAS DataBase Reference: Methyl 8-fluoro-4-hydroxyquinoline-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 8-fluoro-4-hydroxyquinoline-2-carboxylate(219949-89-0)
• EPA Substance Registry System: Methyl 8-fluoro-4-hydroxyquinoline-2-carboxylate(219949-89-0)

Safety Data

• Hazardous Substances Data: 219949-89-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 8-fluoro-4-hydroxyquinoline-2-carboxylate is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of various drugs. Its unique properties, including the presence of a fluorine atom, contribute to the development of new and effective medications.
Used in Agrochemical Industry:
Methyl 8-fluoro-4-hydroxyquinoline-2-carboxylate is used as an intermediate in the synthesis of agrochemicals, particularly pesticides. Its molecular structure allows for the creation of compounds that can effectively target and control pests, thereby enhancing crop protection and yield.
Used in Chemical Reactions:
Methyl 8-fluoro-4-hydroxyquinoline-2-carboxylate is used as a building block in various chemical reactions due to its unique molecular structure. The presence of the fluorine atom can provide specific reactivity and selectivity in chemical processes, making it a valuable component in the synthesis of complex organic compounds.

Upstream product

• 110163-28-5 methyl 2-[(2-fluorophenyl)amino]but-2-enedioate 
• 1314141-66-6 dimethyl (2E)-2-[(2-fluorophenyl)amino]but-2-enedioate 
• 348-54-9 2-Fluoroaniline 
• 762-42-5 dimethyl acetylenedicarboxylate 

Downstream Products

• 1432730-60-3 8-fluoro-4-(4-fluorophenyl)quinoline-2-carboxamide 
• 1432731-49-1 8-fluoro-4-(4-fluorophenyl)quinoline-2-carboxylic acid 

Relevant articles and documents

Acylhydrazone Switches: E/Z Stability Reversed by Introduction of Hydrogen Bonds

We report a series of acylhydrazone-based switches, of which double bond rotation can be stimulated by a pH response. The switches prefer Z rather than E configuration in the ground state because of the intramolecular hydrogen bonding, which was analyzed both thermodynamically and kinetically. Solvation studies show a linear relationship between the isomerization energy in Z/E states (ΔGE/Zo) of the switches and the hydrogen bond basicity scales (β and DN) of the solvent. This solvent effect was also found to be relative to the skeleton of compound, the less shield of hydrogen bond domain the more sensitivity to the solvent environment. By introducing multiple intramolecular hydrogen bonds, the Z isomer completely predominates for compound 4, offering an advantage over a full E/Z isomerization switching.

QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE

The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.

QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to quinoline amide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Compositions derived from quinoline and quinoxaline, preparation and use thereof

The present invention concerns compounds derived from quinoline and quinoxaline, their preparation and their uses, particularly in the field of therapeutics and vaccines or for developing active compounds. The inventive compounds are of general formula (I